Do analysts prefer APVO or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation and earnings, APVO or ABP?

Abpro is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is APVO or ABP more profitable?

Abpro's return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Abpro N/A N/A -344.76%

Do analysts prefer ABP or ADIL?

Adial Pharmaceuticals has a consensus price target of $17.17, indicating a potential upside of 566.67%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Abpro. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Adial Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has stronger earnings & valuation, ABP or ADIL?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A

Is ABP or ADIL more profitable?

Abpro's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Adial Pharmaceuticals N/A -162.82% -127.58%

Do analysts recommend PULM or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation & earnings, PULM or ABP?

Pulmatrix has higher revenue and earnings than Abpro. Pulmatrix is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmatrix $7.81M 0.77 -$5.16M -$1.23 N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is PULM or ABP more profitable?

Abpro's return on equity of 0.00% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Pulmatrix N/A -107.84% -91.58% Abpro N/A N/A -344.76%

Does the media refer more to PULM or ABP?

In the previous week, Pulmatrix had 2 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Pulmatrix and 1 mentions for Abpro. Pulmatrix's average media sentiment score of 1.21 beat Abpro's score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmatrix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abpro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate APM or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, APM or ABP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group N/A N/A -$1.36M N/A N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is APM or ABP more profitable?

Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Abpro N/A N/A -344.76%

Does the media favor APM or ABP?

In the previous week, Aptorum Group had 2 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Aptorum Group and 1 mentions for Abpro. Aptorum Group's average media sentiment score of 0.30 beat Abpro's score of 0.00 indicating that Aptorum Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abpro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MBIO or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation and earnings, MBIO or ABP?

Mustang Bio is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mustang Bio N/A N/A -$1.92M -$0.48 N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is MBIO or ABP more profitable?

Abpro's return on equity of 0.00% beat Mustang Bio's return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -35.38% -16.36% Abpro N/A N/A -344.76%

Abpro (ABP) Competitors

$0.52 0.00 (0.00%)

As of 06/26/2026

Compare

ABP vs. APVO, ADIL, PULM, APM, and MBIO

Should you buy Abpro stock or one of its competitors? MarketBeat compares Abpro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abpro include Aptevo Therapeutics (APVO), Adial Pharmaceuticals (ADIL), Pulmatrix (PULM), Aptorum Group (APM), and Mustang Bio (MBIO). These companies are all part of the "pharmaceutical products" industry.

How does Abpro compare to Aptevo Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Abpro is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 1 articles in the media. Aptevo Therapeutics' average media sentiment score of 1.89 beat Abpro's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Very Positive
Abpro	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Abpro's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Abpro	N/A	N/A	-344.76%

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 13.7% of Abpro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Aptevo Therapeutics and Abpro tied by winning 5 of the 10 factors compared between the two stocks.

How does Abpro compare to Adial Pharmaceuticals?

Abpro (NASDAQ:ABP) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

23.3% of Abpro shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

Adial Pharmaceuticals has a consensus price target of $17.17, indicating a potential upside of 566.67%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Abpro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Adial Pharmaceuticals and 1 mentions for Abpro. Adial Pharmaceuticals' average media sentiment score of 0.44 beat Abpro's score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Adial Pharmaceuticals	Neutral

Abpro's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Summary

Abpro and Adial Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Abpro compare to Pulmatrix?

Pulmatrix (NASDAQ:PULM) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Pulmatrix has higher revenue and earnings than Abpro. Pulmatrix is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.77	-$5.16M	-$1.23	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

In the previous week, Pulmatrix had 2 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Pulmatrix and 1 mentions for Abpro. Pulmatrix's average media sentiment score of 1.21 beat Abpro's score of 0.00 indicating that Pulmatrix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmatrix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abpro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Comparatively, 13.7% of Abpro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Abpro's return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-107.84%	-91.58%
Abpro	N/A	N/A	-344.76%

Summary

Pulmatrix beats Abpro on 6 of the 11 factors compared between the two stocks.

How does Abpro compare to Aptorum Group?

Aptorum Group (NASDAQ:APM) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Aptorum Group had 2 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Aptorum Group and 1 mentions for Abpro. Aptorum Group's average media sentiment score of 0.30 beat Abpro's score of 0.00 indicating that Aptorum Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptorum Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abpro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Abpro	N/A	N/A	-344.76%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	N/A	N/A	-$1.36M	N/A	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Aptorum Group beats Abpro on 5 of the 7 factors compared between the two stocks.

How does Abpro compare to Mustang Bio?

Mustang Bio (NASDAQ:MBIO) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Mustang Bio is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

Abpro's return on equity of 0.00% beat Mustang Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-35.38%	-16.36%
Abpro	N/A	N/A	-344.76%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Mustang Bio had 1 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Mustang Bio and 1 mentions for Abpro. Mustang Bio's average media sentiment score of 0.43 beat Abpro's score of 0.00 indicating that Mustang Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Mustang Bio	Neutral
Abpro	Neutral

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 4.0% of Mustang Bio shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Mustang Bio and Abpro tied by winning 5 of the 10 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABP vs. The Competition

Export

Metric	Abpro	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.42M	$3.64B	$6.76B	$12.51B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-0.12	21.05	25.78	24.73
Price / Sales	N/A	343.87	548.02	103.35
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	-0.06	8.74	10.84	6.52
Net Income	-$7.23M	$23.81M	$3.57B	$336.86M
7 Day Performance	N/A	3.68%	2.43%	1.31%
1 Month Performance	N/A	1.64%	0.76%	0.36%
1 Year Performance	-91.82%	69.92%	36.68%	30.89%

Abpro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABP Abpro	0.0357 of 5 stars	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
APVO Aptevo Therapeutics	1.3606 of 5 stars	$4.80 +5.7%	N/A	-91.8%	$5.66M	N/A	N/A	50	News Coverage Positive News Gap Down
ADIL Adial Pharmaceuticals	2.322 of 5 stars	$2.75 +8.3%	$17.17 +524.2%	-69.1%	$5.44M	N/A	N/A	20	Gap Down
PULM Pulmatrix	1.2753 of 5 stars	$1.50 +0.7%	N/A	-76.4%	$5.44M	$7.81M	N/A	20	Positive News Short Interest Decrease
APM Aptorum Group	0.6963 of 5 stars	$0.87 +3.3%	N/A	-20.4%	$5.35M	$430K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABP) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abpro (ABP) Competitors

ABP vs. APVO, ADIL, PULM, APM, and MBIO

How does Abpro compare to Aptevo Therapeutics?

Summary

How does Abpro compare to Adial Pharmaceuticals?

Summary

How does Abpro compare to Pulmatrix?

Summary

How does Abpro compare to Aptorum Group?

Summary

How does Abpro compare to Mustang Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abpro (ABP) Competitors

ABP vs. APVO, ADIL, PULM, APM, and MBIO

How does Abpro compare to Aptevo Therapeutics?

Which has preferable valuation and earnings, APVO or ABP?

Does the media refer more to APVO or ABP?

Do analysts prefer APVO or ABP?

Is APVO or ABP more profitable?

Do institutionals & insiders hold more shares of APVO or ABP?

Summary

How does Abpro compare to Adial Pharmaceuticals?

Do insiders & institutionals have more ownership in ABP or ADIL?

Which has stronger earnings & valuation, ABP or ADIL?

Do analysts prefer ABP or ADIL?

Does the media refer more to ABP or ADIL?

Is ABP or ADIL more profitable?

Summary

How does Abpro compare to Pulmatrix?

Which has preferable valuation & earnings, PULM or ABP?

Does the media refer more to PULM or ABP?

Do analysts recommend PULM or ABP?

Do institutionals & insiders have more ownership in PULM or ABP?

Is PULM or ABP more profitable?

Summary

How does Abpro compare to Aptorum Group?

Does the media favor APM or ABP?

Do analysts rate APM or ABP?

Is APM or ABP more profitable?

Which has better valuation & earnings, APM or ABP?

Do institutionals & insiders believe in APM or ABP?

Summary

How does Abpro compare to Mustang Bio?

Which has higher valuation and earnings, MBIO or ABP?

Is MBIO or ABP more profitable?

Do analysts prefer MBIO or ABP?

Does the media favor MBIO or ABP?

Do institutionals and insiders have more ownership in MBIO or ABP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools